189506-47-6

Basic information

• Product Name: 2-Amino-1-(3-methoxy-phenyl)-ethanone
• Synonyms: 2-Amino-1-(3-methoxy-phenyl)-ethanone
• CAS NO: 189506-47-6
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 165.18914
• Mol File: 189506-47-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Amino-1-(3-methoxy-phenyl)-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-1-(3-methoxy-phenyl)-ethanone(189506-47-6)
• EPA Substance Registry System: 2-Amino-1-(3-methoxy-phenyl)-ethanone(189506-47-6)

Safety Data

• Hazardous Substances Data: 189506-47-6(Hazardous Substances Data)

Upstream product

• 586-37-8 1-(3-Methoxyphenyl)ethanone 
• 14367-85-2 1-(3-methoxyphenyl)-2-nitroethan-1-one 
• 5000-65-7 2-bromo-3'-methoxyacetophenone 
• 194787-89-8 2-azido-1-(3-methoxyphenyl)ethan-1-one 

Downstream Products

• 35746-82-8 N-2-[2-(3-methoxy-phenyl)-2-oxo-ethyl]acetamide 
• 912762-33-5 tert-butyl (2-(3-methoxyphenyl)-2-oxoethyl)carbamate 
• 138809-94-6 (S)-(+)-2-(3-methoxyphenyl)oxirane 
• 344359-58-6 N-[3-cyano-4-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-formamidine 
• 194787-34-3 5-(3-Methoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl-amine 
• 194787-90-1 2-amino4-(3-methoxy-phenyl)-1H-pyrrole-3-carbonitrile 
• 912762-85-7 tert-butyl [2-amino-2-(3-methoxyphenyl)ethyl]carbamate 
• 912762-53-9 C₁₄H₂₀N₂O₄ 

Relevant articles and documents

BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR

The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof.

Polysubstituted quinazoline derivatives, and preparation method, pharmaceutical composition and application thereof

The invention relates to polysubstituted quinazoline derivatives, and a preparation method, a pharmaceutical composition and application thereof. The polysubstituted quinazoline derivatives are represented by formula (I), are a PI3K/HDAC dual inhibitor and can be used for preventing and/or treating diseases related to PI3K and/or HDAC activity, such as tumors, autoimmune diseases, kidney diseases,cardiovascular diseases, inflammation, metabolic/endocrine dysfunction or neurological diseases.

Antifungal benzo[b]thiophene 1,1-dioxide IMPDH inhibitors exhibit pan-assay interference (PAINS) profiles

Fungi cause serious life-threatening infections in immunocompromised individuals and current treatments are now complicated by toxicity issues and the emergence of drug resistant strains. Consequently, there is a need for development of new antifungal drugs. Inosine monophosphate dehydrogenase (IMPDH), a key component of the de novo purine biosynthetic pathway, is essential for growth and virulence of fungi and is a potential drug target. In this study, a high-throughput screen of 114,000 drug-like compounds against Cryptococcus neoformans IMPDH was performed. We identified three 3-((5-substituted)-1,3,4-oxadiazol-2-yl)thio benzo[b]thiophene 1,1-dioxides that inhibited Cryptococcus IMPDH and also possessed whole cell antifungal activity. Analogs were synthesized to explore the SAR of these hits. Modification of the fifth substituent on the 1,3,4-oxadiazole ring yielded compounds with nanomolar in vitro activity, but with associated cytotoxicity. In contrast, two analogs generated by substituting the 1,3,4-oxadiazole ring with imidazole and 1,2,4-triazole gave reduced IMPDH inhibition in vitro, but were not cytotoxic. During enzyme kinetic studies in the presence of DTT, nucleophilic attack of a free thiol occurred with the benzo[b]thiophene 1,1-dioxide. Two representative compounds with substitution at the 5 position of the 1,3,4-oxadiazole ring, showed mixed inhibition in the absence of DTT. Incubation of these compounds with Cryptococcus IMPDH followed by mass spectrometry analysis showed non-specific and covalent binding with IMPDH at multiple cysteine residues. These results support recent reports that the benzo[b]thiophene 1,1-dioxides moiety as PAINS (pan-assay interference compounds) contributor.

Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors

Inhibition of sphingosine-1-phosphate lyase has recently been proposed as a potential treatment option for inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. In this report we describe our hit-to-lead evaluation of the isoxazolecarboxamide 6, a high-throughput screening hit (in vitro IC50 = 1.0 μM, cell IC50 = 1.8 μM), as a novel S1P lyase inhibitor. We were able to establish basic structure-activity relationships around 6 and succeeded in obtaining X-ray structural information which enabled structure-based design. With the discovery of 28, enzyme activity was quickly improved to IC50 = 120 nM and cell potency to IC50 = 230 nM. The main liability in the established isoxazolecarboxamide hit series was determined to be metabolic stability. In particular we identified that future lead-optimization efforts to overcome this problem should focus on blocking the N-dealkylation on the secondary amine.

7-alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines - Potent inhibitors of the tyrosine kinase c-Src

7-Substituted-5-aryl-pyrrolo[2,3-d]pyrimidines have been prepared starting from α-bromoacetophenones. These compounds represent a novel class of potent inhibitors of the tyrosine kinase pp60c-Src with good specificity towards other tyrosine kinases (EGF-R, v-Abl).